NEW YORK, Sept. 15 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX) announced today that it has appointed Frank Murdolo, Vice
President - Investor Relations.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO)
Mr. Murdolo joins Forest following eleven years with GlaxoSmithKline
PLC where he was Vice President of Investor Relations, with overall
responsibility for managing the North American investor relations program.
Prior to joining GSK, he worked for the Schering-Plough Corporation as the
Director of Investor Relations for six years and earlier in roles of
increasing responsibility within the Schering Finance organization.
Frank Perier, Jr., Forest's Senior Vice President - Finance and Chief
Financial Officer, commented: "We are very pleased to have a person with
Frank Murdolo's extensive experience with both the financial community and
the pharmaceutical industry join Forest as the Company's principal external
spokesperson. As the Company continues to grow and build its pipeline of
products for the future, Frank's knowledge, experience and reputation will
be of great value to the Company and its investors."
About Forest Laboratories
Forest Laboratories (NYSE: FRX) is a US-based pharmaceutical company
with a long track record of building partnerships and developing and
delivering products that make a positive difference in people's lives. In
addition to its well-established franchises in therapeutic areas of the
central nervous and cardiovascular systems, Forest's current pipeline
includes product candidates in all stages of development and across a wide
range of therapeutic areas. The company is headquartered in New York, NY.
To learn more about Forest Laboratories, visit http://www.FRX.com.
Except for the historical information contained herein, this release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements involve a number
of risks and uncertainties, including the difficulty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to time in
Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and any subsequent SEC filings.
SOURCE Forest Laboratories, Inc.
 back to top
Related links:
http://www.frx.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Frank Murdolo, Vice President - Investor
Relations, Forest Laboratories, Inc., +1-212-224-6714,
Frank.Murdolo@frx.com
|
